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Diagnostic and therapies 
Materials and methods 
The samples for study the possible diagnosis of PDAC were obtained of 
PDAC tissues. Firstly was made an RNA extraction, and after it were used 
the methods of quantitative real-time PCR and microarray technology for 
detect the miRNAs overexpressed.  
For study possible therapies against PDAC were used the cell lines L3.6pl 
and Hs776T and the antagomirs miR-10b, miR-21, miR-221 and miR-222. 
The methods used include, encapsulation of antagomirs in lipoplexes, RNA 
extraction and quantitative real-time PCR. 
Pancreatic ductal adenocarcinoma 
Due to the action of different signaling pathways controlled by the 
transcription factor FOXM1 the PanIN could develop to PDAC. 
There is an aberrant expression of the gens controlled by FOXM1 
(KRAS,TP53, CDKN2A, and SMAD4) during the different states 
of the lesion, which at the end could become PDAC. Also there 
are some miRNAs that have an altered expression, such as miR-
21, miR-34a,miR-155 and the family of miR-200. 
Epithelial to Mesenchymal transition 
The process of EMT alters the 
integrity of cell–cell junctions, 
promoting loss of polarity and 
epithelial markers, resulting in loss of 
contact between neighboring cells. 
Due to this process, tumor cells 
become more mesenchymal-like, 
exhibiting higher migratory and 
invasive properties that allow them to 
interact with the extracellular matrix 
and invade surrounding tissues 
promoting metastasis. The principal 
families of transcription factors 
involved in this process are Snail, 
BhLH, ZEB and the transcription 
factor VEGF-β. Also there is an 
alteration in some miRNAs like miR-
1, miR-29b, miR-34a, and the family 
of miR-200 
Figure 2. Schema of the complex 
metastatic process. Epithelial–
mesenchymal transition (EMT) alters the 
cell phenotype to allow intravasation into 
the systemic circulation. 
Introduction 
Pancreatic Ductal Adenocarcinoma (PDAC) it’s one of the most lethal carcinomas. The overall median survival is 2–8 months, and only 1%–4% of all the 
patients with PDAC survive for more than 5 years. The epithelial-mesenchymal transition (EMT) it’s a process in which the epithelial cells change their 
properties into motile mesenchymal cells playing an important role in conferring metastatic properties in many solid tumors like the PDAC. Both processes, 
PDAC and EMT, have aberrant expressions of transcription factors and miRNAs, molecules that control the cell cycle, apoptosis, differentiation, proliferation 
and response to cellular stressors. The aim of this final degree project it’s make a revision of the different transcription factors and miRNAs involved in this 
two processes and propose a few therapies and diagnostics, based in measuring and controlling the expression of miRNAs, that can help to make an early 
diagnostic of the PDAC and control or stop the development of the disease. 
Figure 1. Development  of the PDAC and aberrant expression of the principal 
genes involved. 
• The change in the expression of the miRNAs can be used in the diagnostic of the pancreatic cancer. A recent study showed that miR-21 and miR-34a are 
the most useful miRNAs as biomarkers. The results demonstrated that high expression of miR-21 and down expression of miR34a is related with poor 
prognosis of the pancreatic cancer. Also the upregulation of miR-221/222 miRNAs promotes the proliferation of tumors in PDAC cell lines. 
•  In another study was evaluated the utility of miR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers of PDAC. The results 
showed an increase in the levels of miR-21 and miR-198 and a decreased level of miR-217 in the PDAC tissue.The high levels of miR-21 and miR-198 
were significantly correlated with poor prognosis. Furthermore, the high expression of miR-21 was related with a poor response to the chemotherapeutic 
agent gemcitabine.  
• Recent studies showed that is possible to inhibit the expression of miRNAs using antagomirs. A combined therapy using antagomirs against miR-21 and 
miR-221 lead to a change of the expression in more than 1300 genes in a highly metastatic human pancreatic cancer cell line (L3.6pl), and reduced the 
proliferation and invasion of this tumor cells and also helps to the reconstitution of sensitivity to different chemotherapeutic agents like 5-fluoracil or 
gemcitabine. 
•  Another therapeutic option using antagomirs was founded, using lipoplexes containing antagomirs against miR-21, miR-221 and miR-221. The results of 
the work showed that the administration of a nanosystem called, HSA-EPOPC:Chol/AMOs (+/-) has the ability of efficiently deliver the antagomirs into the 
tumor cells of PDAC. These administrated antagomirs achieved and almost total inhibition of the principal miRNAs involved in pancreatic cancer, such as 
miR-21, miR-221, and miR-222; aberrantly expressed in this cancer model.  
 
 
 
 
 
• The EMT it’s a crucial process in the developing of PDAC, and 
controlling the principal pathways involved on it could be the key for 
cure the disease. 
• The results of these recent studies showed that the most useful 
miRNAs for the diagnosis and prognosis of the PDAC are the miR-
21, miR-34a, miR-198 and the miR-200 family.  
• Antagomirs against the miRNA-21 and the family of miRNA-200 are 
showing promising reduction of the cell viability and could be a 
suitable therapy in the future.  
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